Form 4: Sarepta Director Exercises Options, Withholds Shares

Sarepta Therapeutics Director M. Kathleen Behrens exercised stock options and had shares withheld to cover the exercise price.

Summary

• M. Kathleen Behrens, a Director at Sarepta Therapeutics, Inc. (SRPT), exercised 10,500 stock options on January 27, 2026.
• The exercise price for these options was $13.71 per share.
• Concurrently, 6,494 shares of Common Stock were withheld by the Issuer at a price of $22.17 per share to satisfy the payment of the option exercise price.
• Following these transactions, M. Kathleen Behrens' direct beneficial ownership of Common Stock is 197,482 shares.
• She also indirectly owns 10,000 shares of Common Stock through a Trust.
• The exercised stock options were exercisable since February 28, 2017, and were set to expire on February 28, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine insider transaction related to equity compensation rather than a significant change in company fundamentals or strategic direction.

Positives

• The exercise of options indicates a director realizing value from previously granted equity, which can be seen as a positive for the individual.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned transaction rather than a reaction to immediate market conditions.

Negatives

• The withholding of shares to cover the exercise price results in a net decrease in the director's direct beneficial ownership of common stock by 6,494 shares, which could be interpreted as a slight reduction in direct exposure.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions like option exercises and share withholdings are routine events in publicly traded companies, reflecting the compensation structure for executives and directors. These transactions are typically company-specific and do not inherently reflect broader industry trends, though the underlying stock performance that makes options valuable is influenced by industry dynamics.

Related Party Transactions

• The exercise of stock options and subsequent share withholding by a director constitutes a related party transaction, as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The net change in direct beneficial ownership is minor and part of routine compensation. It does not significantly alter the overall ownership structure or control.
• Employees: No direct impact on employees is indicated by this filing.
• Management: The transaction reflects a director realizing value from their equity compensation, which is a standard aspect of executive and director remuneration.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of stock options and subsequent share withholding for tax purposes. It does not provide new information regarding the company's operational performance, financial health, or strategic outlook that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this event is neutral to the company's intrinsic value.

Keywords

Sarepta Therapeutics, SRPT, Form 4, Insider Trading, Stock Options, Director Transaction, Equity Compensation, Share Withholding, M. Kathleen Behrens, SEC Filing